Search research articles
Contact Us
Filters
Showing results (191-200 of 485) with videos related to
Page
of 49
Sort By:
Vaccine
|
July 21, 2005
Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults
Maarten J Postma, Paul Jansema, Huib W K F H Scheijbeler, et al.
Pharmacoeconomics
|
February 8, 2006
Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands
Jasper M Bos, Hans C Rümke, Robert Welte, et al.
The Lancet. Global Health
|
November 26, 2022
Clinical and economic burden of drug-susceptible tuberculosis in Indonesia: national trends 2017-19
Deni Iskandar, Auliya A Suwantika, Ivan S Pradipta, et al.
Expert Opinion on Pharmacotherapy
|
January 13, 2021
Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?
Tanja Fens, Guiling Zhou, Maarten J Postma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 2, 2008
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model
Beate Sander, Azhar Nizam, Louis P Garrison, et al.
BMC Health Services Research
|
November 1, 2019
Diabetes distress in Indonesian patients with type 2 diabetes: a comparison between primary and tertiary care
Bustanul Arifin, Antoinette D I van Asselt, Didik Setiawan, et al.
Plos One
|
August 6, 2014
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands
Jelena Stevanović, Marjolein Pompen, Hoa H Le, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 29, 2017
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
Maartje S Jacobs, Lisa A de Jong, Maarten J Postma, et al.
Pharmacoeconomics
|
May 10, 2024
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, et al.
Expert Opinion on Pharmacotherapy
|
August 29, 2003
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes
Maarten J Postma, Hanneke Kruidhof, Lolkje T W de Jong-van den Berg, et al.
Page
of 49
Search research articles
Search
Showing results (191-200 of 485) with videos related to
Sort By:
Page
of 49
Vaccine
|
July 21, 2005
Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults
Maarten J Postma, Paul Jansema, Huib W K F H Scheijbeler, et al.
Pharmacoeconomics
|
February 8, 2006
Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands
Jasper M Bos, Hans C Rümke, Robert Welte, et al.
The Lancet. Global Health
|
November 26, 2022
Clinical and economic burden of drug-susceptible tuberculosis in Indonesia: national trends 2017-19
Deni Iskandar, Auliya A Suwantika, Ivan S Pradipta, et al.
Expert Opinion on Pharmacotherapy
|
January 13, 2021
Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?
Tanja Fens, Guiling Zhou, Maarten J Postma, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 2, 2008
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model
Beate Sander, Azhar Nizam, Louis P Garrison, et al.
BMC Health Services Research
|
November 1, 2019
Diabetes distress in Indonesian patients with type 2 diabetes: a comparison between primary and tertiary care
Bustanul Arifin, Antoinette D I van Asselt, Didik Setiawan, et al.
Plos One
|
August 6, 2014
Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands
Jelena Stevanović, Marjolein Pompen, Hoa H Le, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 29, 2017
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
Maartje S Jacobs, Lisa A de Jong, Maarten J Postma, et al.
Pharmacoeconomics
|
May 10, 2024
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, et al.
Expert Opinion on Pharmacotherapy
|
August 29, 2003
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes
Maarten J Postma, Hanneke Kruidhof, Lolkje T W de Jong-van den Berg, et al.
Page
of 49